Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Moderna, Inc. Stock

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 08:00:00 07/02/25 am AEDT 		5-day change 1st Jan Change
33.61 USD -3.92% Intraday chart for Moderna, Inc. -18.10% -19.17%
05/02 Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr. DJ
04/02 Wall Street: digesting the shock of the 'tariffs', Tesla falls 5%. CF

Valuation: Moderna, Inc.

Capitalization 12.93B 12.47B 11.7B 10.39B 18.5B 1,133B 20.58B 141B 52.25B 464B 48.46B 47.51B 1,964B P/E ratio 2024 *
-3.68x
P/E ratio 2025 * -3.7x
Enterprise value 5.26B 5.07B 4.76B 4.23B 7.53B 461B 8.37B 57.39B 21.26B 189B 19.72B 19.33B 799B EV / Sales 2024 *
1.63x
EV / Sales 2025 * 3.84x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Moderna, Inc.

Dynamic Chart

Latest news: Moderna, Inc.

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr. 05/02 DJ
Wall Street: digesting the shock of the 'tariffs', Tesla falls 5%. 04/02 CF
Moderna Shares Fall After TD Cowen Cuts Price Target 30/01 MT
TD Cowen Adjusts Price Target on Moderna to $35 From $55, Keeps Hold Rating 30/01 MT
Is Wall Street Ready to Move Past DeepSeek? 30/01Our Logo
Analyst recommendations: Mondi, Admiral, Severn Trent, Coinbase, Verizon, Moderna… 29/01Our Logo
Analyst recommendations: At&T, Caterpillar, Coinbase, Verizon, Moderna… 29/01Our Logo
Goldman Sachs Downgrades Moderna to Neutral From Buy, Adjusts Price Target to $51 From $99 29/01 MT
Evercore ISI Adjusts Moderna Price Target to $50 From $60, Maintains In Line Rating 28/01 MT
Goldman Sachs Adjusts Price Target on Moderna to $99 From $112, Keeps Buy Rating 27/01 MT
JPMorgan Adjusts Price Target on Moderna to $40 From $45, Maintains Underweight Rating 27/01 MT
Health Care Up on Novo Nordisk Optimism -- Health Care Roundup 25/01 DJ
S&P 500 Posts Weekly Gain Amid Earnings Beats, Start of Trump Presidency 25/01 MT
More news

Last Transcript: Moderna, Inc.

Logo Moderna, Inc.
Moderna, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM
14/01
More transcripts

Analysts' recommendations: Moderna, Inc.

TD Cowen Adjusts Price Target on Moderna to $35 From $55, Keeps Hold Rating 30/01 MT
Analyst recommendations: Mondi, Admiral, Severn Trent, Coinbase, Verizon, Moderna… 29/01Our Logo
Analyst recommendations: At&T, Caterpillar, Coinbase, Verizon, Moderna… 29/01Our Logo
Goldman Sachs Downgrades Moderna to Neutral From Buy, Adjusts Price Target to $51 From $99 29/01 MT
Evercore ISI Adjusts Moderna Price Target to $50 From $60, Maintains In Line Rating 28/01 MT
More recommendations

Press Releases: Moderna, Inc.

Moderna reports record for UK clinical trials in 2023/24 04/02 AQ
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union 28/01 AQ
Moderna Announces Updates on Pandemic Influenza Program 21/01 AQ
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference 15/01 AQ
Moderna surprises the Street by predicting a bigger-than-expected sales drop 14/01 AQ
More press releases

News in other languages: Moderna, Inc.

Valores destacados al cierre del mercado norteamericano 05/02
Wall Street : digère le choc des 'tarifs', Tesla chute de 5% 04/02
Lonza freiné en 2024 après l'échéance du contrat avec Moderna 30/01
Valores destacados al cierre del mercado norteamericano 29/01
Ausblick Lonza: Jahresumsatz von 6,6 Milliarden Franken erwartet 29/01
More news

Quotes and Performance

1 day-3.92%
1 week-18.10%
Current month-14.74%
1 month-21.05%
3 months-35.13%
6 months-59.16%
Current year-19.17%
More quotes

Course Extremes

1 week
33.61
Extreme 33.61
38.65
1 month
31.94
Extreme 31.94
47.70
Current year
31.94
Extreme 31.94
48.92
1 year
31.94
Extreme 31.94
170.47
3 years
31.94
Extreme 31.94
217.25
5 years
17.91
Extreme 17.91
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes

Managers and Directors: Moderna, Inc.

Director TitleAgeSince
Stéphane Bancel CEO
 Chief Executive Officer 52 01/03/2011
James Mock DFI
 Director of Finance/CFO 48 06/09/2022
Stephen Hoge PSD
 President 49 01/02/2015
Manager TitleAgeSince
Paul Sagan BRD
 Director/Board Member 66 01/06/2018
Noubar Afeyan CHM
 Chairman 61 01/02/2012
Stéphane Bancel BRD
 Director/Board Member 52 01/03/2011
More insiders

ETFs: Moderna, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
5.66% 0 M€ 0.00% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.69% 0 M€ -.--% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
4.08% 0 M€ 0.00% -
More ETFs: Moderna, Inc.

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
MODERNA, INC. Stock Moderna, Inc.
-3.92%-18.10%-66.40%-79.38%12.93B
LONZA GROUP AG Stock Lonza Group AG
-0.23%+3.76%+37.04%-1.67%48.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.20%+4.05%-2.53%-15.98%38.11B
CELLTRION, INC. Stock Celltrion, Inc.
+1.51%+0.44%+3.85%+24.70%26.56B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
-0.24%-2.87%-26.19%-26.62%16.18B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
-0.12%+0.41%+64.57%+75.48%15.79B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.32%+3.09%+11.34%-26.83%11.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+1.64%+3.12%+19.29%+110.17%11.19B
TEMPUS AI, INC. Stock Tempus AI, Inc.
-6.06%+13.64% - - 10.23B
QIAGEN N.V. Stock Qiagen N.V.
-3.11%-4.65%-7.90%-19.58%9.17B
Average +0.04%+0.25%+3.68%+4.48% 20.1B
Weighted average by Cap. +0.35%+1.05%+9.62%+2.28%
See all sector performances

Financials

2024 *2025 *
Net sales 3.22B 3.11B 2.92B 2.59B 4.61B 282B 5.13B 35.15B 13.02B 116B 12.08B 11.84B 490B 2.2B 2.12B 1.99B 1.77B 3.15B 193B 3.51B 24.03B 8.9B 79.07B 8.26B 8.09B 335B
Net income -3.5B -3.38B -3.17B -2.81B -5.01B -307B -5.57B -38.19B -14.15B -126B -13.12B -12.87B -532B -3.53B -3.4B -3.19B -2.84B -5.05B -309B -5.62B -38.48B -14.26B -127B -13.22B -12.96B -536B
Net Debt -7.67B -7.39B -6.94B -6.16B -10.97B -672B -12.21B -83.64B -30.99B -275B -28.74B -28.17B -1,165B -4.46B -4.3B -4.04B -3.59B -6.38B -391B -7.1B -48.66B -18.03B -160B -16.72B -16.39B -678B
More financial data * Estimated data

Company Profile

Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).
Employees
5,600
Sector
Biotechnology & Medical Research
Calendar
14/02/2025 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
06/02/25 33.61 $ -3.92% 8,978,842
05/02/25 34.98 $ +2.37% 9,386,550
04/02/25 34.17 $ -6.51% 22,904,917
03/02/25 36.55 $ -7.28% 13,511,794
31/01/25 39.42 $ -3.95% 6,538,798

Delayed Quote Nasdaq, 07 February 2025 at 08:00 am AEDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
33.61USD
Average target price
62.32USD
Spread / Average Target
+85.43%
Consensus
Profit revisions
Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MRNA Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition